Denali unveils $130M funding, series of deals

Denali Therapeutics Inc. (South San Francisco, Calif.) disclosed Thursday that it raised $130 million in a series B round and made five deals to flesh out its pipeline. The company is pursuing neurodegenerative diseases including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.

Closed in June, the B round was led by Baillie Gifford and included all of Denali's founding investors, along with multiple undisclosed new investors. In May 2015, Denali raised $217 million in a series A round that included Fidelity Biosciences, Arch Venture Partners, Flagship Ventures, the Alaska Permanent Fund and undisclosed investors (see BioCentury, May 18, 2015). ...